Mitochondrial Encephalopathy CRISPR Cell Models for Drug Discovery

Mitochondrial encephalopathy encompasses a group of disorders caused by mutations in mitochondrial DNA (mtDNA) or nuclear genes affecting mitochondrial function. The global prevalence of mitochondrial diseases is estimated at 1 in 5,000 to 1 in 10,000 live births (WHO, 2023). Common subtypes include MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) and MERRF (Myoclonus Epilepsy with Ragged Red Fibers). Clinical impact is severe, with progressive neurological decline, seizures, and stroke-like episodes often leading to disability and premature death. Five-year survival varies by subtype; for MELAS, it is approximately 50% (NCI, 2022). Key risk factors include maternal inheritance for mtDNA mutations and autosomal recessive inheritance for nuclear gene mutations.

Mitochondrial encephalopathy is ideal for mechanistic studies due to its well-defined genetic basis and tissue-specific manifestations. Subtypes such as MELAS (MT-TL1 mutation) and MERRF (MT-TK mutation) provide clear genotype-phenotype correlations. Public datasets, including the Mitochondrial Disease Sequence Data Resource (MSeqDR) and ClinVar, offer extensive variant information. Open questions include the role of heteroplasmy thresholds, tissue-specific vulnerability, and the interplay between mitochondrial and nuclear genomes. Gene-edited cell models allow precise manipulation of these genetic factors, enabling functional validation and drug screening.

Mitochondrial encephalopathy arises from defects in oxidative phosphorylation (OXPHOS), leading to energy deficiency and cellular stress. Key pathways include:

1. OXPHOS impairment: Mutations in mtDNA-encoded tRNA genes (e.g., MT-TL1, MT-TK) disrupt mitochondrial protein synthesis, reducing complex I, III, IV, and V activity.

• • Decreased ATP production.
• • Increased reactive oxygen species (ROS).
• • Activation of the mitochondrial unfolded protein response (UPRmt).

2. Mitochondrial dynamics dysregulation: Mutations in nuclear genes (e.g., MFN2, OPA1) impair fusion/fission, leading to fragmented mitochondria and impaired mitophagy.

• • Accumulation of damaged mitochondria.
• • Activation of apoptosis via cytochrome c release.

3. Metabolic reprogramming: Energy deficiency triggers compensatory glycolysis, resulting in lactic acidosis.

• • Upregulation of HIF-1alpha.
• • Increased lactate production.
• • Altered TCA cycle flux.

Data from TCGA (2023) and COSMIC (v99).

Key signaling networks involved:

• • AMPK pathway: Activated by low ATP/AMP ratio, promoting catabolism and mitophagy.
• • Key nodes: AMPK, ULK1, SIRT1.
• • Dysregulation leads to impaired energy sensing.
• • mTOR pathway: Suppressed by energy deficiency, reducing protein synthesis and cell growth.
• • Key nodes: mTORC1, 4E-BP1, S6K.
• • Chronic suppression contributes to neurodegeneration.
• • NF-kB pathway: Activated by ROS and mitochondrial stress, promoting inflammation.
• • Key nodes: IKK, NF-kB, TNF-alpha.
• • Upregulation in affected tissues exacerbates neuronal damage.
• • Apoptotic pathway: Mitochondrial outer membrane permeabilization (MOMP) releases cytochrome c, activating caspases.
• • Key nodes: BAX, BAK, BCL-2, caspase-3.
• • Increased apoptosis in neurons and muscle cells.

Organoids, such as cerebral organoids derived from patient iPSCs, recapitulate tissue-specific mitochondrial dysfunction and allow study of neuronal network effects.

• • Mitochondrial disease mouse models: Transmit heteroplasmic mtDNA mutations (e.g., m.3243A>G) to study systemic effects.
• • POLG mutator mice: Express mutant POLG to induce mtDNA mutations and premature aging.
• • MFN2 knockout mice: Model Charcot-Marie-Tooth disease type 2A with mitochondrial dysfunction.
• • Zebrafish models: Used for high-throughput drug screening due to transparency and genetic tractability.

CRISPR/Cas9 gene editing enables the creation of isogenic cell lines with precise mitochondrial or nuclear gene modifications. Examples include:

• • MT-TL1 knock-in models: Introduction of the m.3243A>G mutation into SH-SY5Y or HEK293 cells to study MELAS.
• • POLG knockout lines: Disruption of POLG in HEK293 cells to model mtDNA depletion.
• • MFN2 knockout lines: Loss of MFN2 in SH-SY5Y cells to study mitochondrial fragmentation.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, isogenic backgrounds for functional studies and drug screening. These models are available from commercial sources and are validated by Sanger sequencing and functional assays (e.g., Seahorse respirometry).

Knockout and knock-in lines validate the role of specific genes in mitochondrial encephalopathy. For example:

• • POLG knockout: Confirms requirement for mtDNA replication; leads to mtDNA depletion and reduced ATP production.
• • MT-TL1 knock-in: Demonstrates that the m.3243A>G mutation impairs complex I activity and increases ROS.
• • MFN2 knockout: Shows that loss of mitochondrial fusion causes fragmented networks and sensitizes cells to stress.

Isogenic pairs (wild-type vs. mutant) enable high-throughput screening for compounds that rescue mitochondrial function. For example:

• • Screening for molecules that increase ATP production in MT-TL1 mutant cells.
• • Testing antioxidants (e.g., MitoQ) for ROS reduction.
• • Modeling resistance to mitochondrial toxins (e.g., rotenone) in POLG-deficient cells.

CRISPR-based synthetic lethality screens identify genes that, when knocked out, selectively kill mutant cells. For example:

• • In POLG-deficient cells, targeting alternative DNA repair pathways (e.g., PARP1) may be synthetically lethal.
• • In MT-TL1 mutant cells, targeting mitochondrial chaperones (e.g., HSP60) may exacerbate stress and induce cell death.